Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX15-IV vs Darzalex in NDMM
NCT06895512Phase 3Not yet recruiting
- Sponsor
- Henlius
- Start
- Apr 2025
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of HLX15-IV in multiple myeloma (MM), sponsored by Henlius. Primary endpoint: Rate of Very Good Partial Response (VGPR) or Better at 24 weeks. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
HLX15-IV
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06895512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06895512.